Cube-shaped theranostic paclitaxel prodrug nanocrystals with surface functionalization of SPC and MPEG-DSPE for imaging and chemotherapy

Drug Nanocrystals for Active Tumor-Targeted Drug Delivery

Drug nanocrystals, which are comprised of active pharmaceutical ingredients and only a small amount of essential stabilizers, have the ability to improve the solubility, dissolution and bioavailability of poorly water-soluble drugs; in turn, drug nanocrystal technology can be utilized to develop novel formulations of chemotherapeutic drugs. Compared with passive targeting strategy, active tumor-targeted drug delivery, typically enabled by specific targeting ligands or molecules modified onto the surface of nanomedicines, circumvents the weak and heterogeneous enhanced permeability and retention (EPR) effect in human tumors and overcomes the disadvantages of nonspecific drug distribution, high administration dosage and undesired side effects, thereby contributing to improving the efficacy and safety of conventional nanomedicines for chemotherapy. Continuous efforts have been made in the development of active tumor-targeted drug nanocrystals delivery systems in recent years, most of which are encouraging and also enlightening for further investigation and clinical translation.

Paclitaxel Drug Delivery Systems: Focus on Nanocrystals' Surface Modifications

Paclitaxel (PTX) is a chemotherapeutic agent that belongs to the taxane family and which was approved to treat various kinds of cancers including breast cancer, ovarian cancer, advanced non-small-cell lung cancer, and acquired immunodeficiency syndrome (AIDS)-related Kaposi’s sarcoma. Several delivery systems for PTX have been developed to enhance its solubility and pharmacological properties involving liposomes, nanoparticles, microparticles, micelles, cosolvent methods, and the complexation with cyclodextrins and other materials that are summarized in this article. Specifically, this review discusses deeply the developed paclitaxel nanocrystal formulations. As PTX is a hydrophobic drug with inferior water solubility properties, which are improved a lot by nanocrystal formulation. Based on that, many studies employed nano-crystallization techniques not only to improve the oral delivery of PTX, but IV, intraperitoneal (IP), and local and intertumoral delivery systems were also developed. Additionally, superior and interesting properties of PTX NCs were achieved by performing additional modifications to the NCs, such as stabilization with surfactants and coating with polymers. This review summarizes these delivery systems by shedding light on their route of administration, the methods used in the preparation and modifications, the in vitro or in vivo models used, and the advantages obtained based on the developed formulations.

Carrier-free nanodrugs with efficient drug delivery and release for cancer therapy: From intrinsic physicochemical properties to external modification

The considerable development of carrier-free nanodrugs has been achieved due to their high drug-loading capability, simple preparation method, and offering "all-in-one" functional platform features. However, the native defects of carrier-free nanodrugs limit their delivery and release behavior throughout the in vivo journey, which significantly compromise the therapeutic efficacy and hinder their further development in cancer treatment. In this review, we summarized and discussed the recent strategies to enhance drug delivery and release of carrier-free nanodrugs for improved cancer therapy, including optimizing the intrinsic physicochemical properties and external modification. Finally, the corresponding challenges that carrier-free nanodrugs faced are discussed and the future perspectives for its application are presented. We hope this review will provide constructive information for the rational design of more effective carrier-free nanodrugs to advance therapeutic treatment.

Synthesis and application of a series of amphipathic chitosan derivatives and the corresponding magnetic nanoparticle-embedded polymeric micelles

Magnetic nanoparticle-embedded polymeric micelles (MNP-PMs) prepared with amphipathic polymers are an important sustained-release carrier for hydrophobic drugs. The amphipathic chitosan derivatives (ACDs) based stimuli-responsive slow-release carriers have attracted considerable attentions because of the bioactivities and modifiability of chitosan. In the current study, a series of ACDs including alkylated N-(2-hydroxy) propyl-3-trimethyl ammonium chitosan chloride (alkyl-HTCC) and alkylated polyethylene glycol N-(2-hydroxy) propyl-3-trimethyl ammonium chitosan chloride (alkyl-PEG-HTCC) were prepared by the reductive amination of HTCC and PEG-HTCC, and their structures and properties were characterized. Octyl-HTCC/O-Fe₃O₄ and octyl-PEG-HTCC/O-Fe₃O₄ MNP-PMs were prepared by the hydrophobic interactions between the corresponding ACDs and oil soluble Fe₃O₄ magnetic nanoparticles (O-Fe₃O₄ MNPs), and characterized for the structure, magnetic performance and surface charge state. Their potential application as a drug delivery carrier was investigated upon the embedding efficiency and pH dependent sustained-release performance using the hydrophobic drug, paclitaxel (PTX), as a model drug. Our work has provided a new application strategy of ACDs in the multi-functional drug delivery carrier.